Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)
4.760
-0.030 (-0.63%)
Jul 29, 2026, 3:04 PM CST
SHE:002793 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 2,373 | 2,273 | 2,647 | 2,364 | 3,588 | 6,478 |
Revenue Growth | -2.78% | -14.12% | 11.99% | -34.11% | -44.62% | 6.26% |
Gross Profit Gross Profit Growth | 1,224 | 1,092 | 1,040 | 1,024 | 893.98 | 3,246 |
Operating Income Operating Income Growth | -152.47 | -158.6 | -476.89 | -479.63 | -1,600 | 519.59 |
Net Income Net Income Growth | -270.08 | -288.58 | -965.5 | -661.14 | -1,225 | 406.1 |
Earnings Per Share EPS Growth | -0.25 | -0.27 | -0.91 | -0.61 | -0.86 | 0.28 |
EPS Growth | - | - | - | - | - | 27.27% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Industry Pharmaceutical Industry Growth | 2,011 | 2,357 | 2,074 | 1,448 | 3,936 |
Pharmaceutical Commercial Pharmaceutical Commercial Growth | 203.56 | 257.93 | 255.06 | 2,022 | 2,433 |
Unallocated Other Business Unallocated Other Business Growth | 59.09 | 32.7 | 35.27 | 117.61 | 108.29 |
Total Total Growth | 2,273 | 2,647 | 2,364 | 3,588 | 6,478 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 806.45 | 554.11 | 457.93 | 695 | 1,451 | 2,034 |
Total Debt Total Debt Growth | 1,227 | 1,098 | 1,640 | 1,520 | 3,622 | 2,858 |
Net Cash (Debt) Net Cash Growth | -420.73 | -543.68 | -1,182 | -825.31 | -2,171 | -823.17 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.40 | -0.51 | -1.11 | -0.76 | -1.52 | -0.57 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 238.2 | 253.07 | -157.85 | 466.89 | -939.13 | 120.63 |
Capital Expenditures CapEx Growth | -30.7 | -32.18 | -115.35 | -242.39 | -194.82 | -309.03 |
Free Cash Flow Free Cash Flow Growth | 207.5 | 220.88 | -273.2 | 224.5 | -1,134 | -188.4 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 51.58% | 48.02% | 39.30% | 43.33% | 24.92% | 50.10% |
Operating Margin | -6.42% | -6.98% | -18.01% | -20.29% | -44.59% | 8.02% |
Pretax Margin | -11.13% | -12.79% | -35.99% | -25.56% | -40.78% | 7.49% |
Profit Margin | -11.38% | -12.69% | -36.47% | -27.97% | -34.14% | 6.27% |
FCF Margin | 8.74% | 9.72% | -10.32% | 9.50% | -31.61% | -2.91% |
| Fiscal Year | FY 2021 |
|---|---|
| Period Ending | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.030 |
Dividend Per Share Growth | -40.00% |
Dividend Yield | 0.29% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | - | 37.38 |
P/FCF Ratio | 24.95 | 23.07 | - | 25.97 | - | - |
PS Ratio | 2.18 | 2.24 | 1.53 | 2.47 | 2.33 | 2.34 |